Boditech Med Inc. es una empresa Corea del Sur, ubicada en 3-2, 3rd Fl., Bio Venture Plaza, 198-60, Hupyeong 1-dong. más detalles se muestran abajo. Información de Empresa Nombre de Empresa: Boditech Med Inc.País: South KoreaDirección: 3-2, 3rd Fl., Bio Venture Plaza, 198-60, Hupyeong 1-dongCódigo de Área Internacional: 82Teléfono: 82-33-258-6884Fax: 82-33-258-6889Contacto: Choi Eui YulPosición: PresidentSitio web: www.boditech.co.krLista de Productos: Diagnostic Reagent,medical DeviceTipo: ManufacturersPerfil: Boditech Med Was Founded In November 1998 By Several College Professors To Exploit The Fluorescence Technology For The Development Of Diagnostic Kits And Their Reader. The Company Is Based In The City Of Chuncheon, 60 Kilometers East Of Seoul, South Korea. Boditech Med Has Raised A Fund From Korean Venture Investment Syndicates And Spent Its Energy In Pursuing The Major R & D In The Field Of Point-of-care Testing (poct). Focusing On New Technologies, New Markets For Near Patient Diagnostic Products, And New Attitudes Of Patients And Healthcare Providers, Boditech Med Is Going Forward Into The Fastest Growing Sector Of Worldwide Diagnostic Industry Whose Products Are Transforming The Practice Of Medicine. The Poc Market For Diagnostic Tests Increases At A Phenomenal Compounded Annual Growth Rate, And Many Parts Of The World Market Is Growing At Comparable Rates. To Comply Market Trend, Boditech Med Developed And Introduced A Poc Fluorescence Reader And Cartridges First Time In The Market 2 Years Ago. Boditech Med Now Launched Its Second Generation Poct System, I- Chromatm, A More Versatile Quantitative Poc Test. The I-chromatm System Has Obtained Clearance Approval On November 2oo2 From Korean Food & Drug Administration (kfda), And Has Received Ce Marking Certification And Lso 13485 On November 2oo4. I-chromatm Can Measure Vascular Inflammation, Tumor Markers, Diabetes, And Some Urine Markers. Más Enlaces Bochun Trading Co. Bock San Co. Ltd. Boditech Med Inc. Body Lab Co. Ltd. Bodycon Co. Ltd. ‹ anterior | siguiente › Inicie sesión para comentar